Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients

E. Mácsai, Á Cseh, G. Budai, G. Mészáros, B. Vásárhelyi, K. Fischer, A. Szabó, A. Treszl

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Doxazosin, an α1-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4+, CD8+, CD25+ and CD69+ cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4 +CD25+high cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4+CD69+ and CD8+CD69+ cells) decreased, whereas that of regulatory Tcells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.

Original languageEnglish
Pages (from-to)1982-1987
Number of pages6
JournalJournal of International Medical Research
Volume37
Issue number6
Publication statusPublished - 2009

Fingerprint

Doxazosin
T-cells
T-Lymphocyte Subsets
Regulatory T-Lymphocytes
Medical problems
Type 2 Diabetes Mellitus
Therapeutics
Blood pressure
Adrenergic Receptors
Blood Glucose
Blood Pressure
Hypertension
T-Lymphocytes
Lipids

Keywords

  • α-Adrenergic receptor inhibitor
  • Doxazosin
  • Immunomodulation
  • Lymphocytes
  • Proteinuria
  • Regulatory T-cells
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Mácsai, E., Cseh, Á., Budai, G., Mészáros, G., Vásárhelyi, B., Fischer, K., ... Treszl, A. (2009). Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients. Journal of International Medical Research, 37(6), 1982-1987.

Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients. / Mácsai, E.; Cseh, Á; Budai, G.; Mészáros, G.; Vásárhelyi, B.; Fischer, K.; Szabó, A.; Treszl, A.

In: Journal of International Medical Research, Vol. 37, No. 6, 2009, p. 1982-1987.

Research output: Contribution to journalArticle

Mácsai, E, Cseh, Á, Budai, G, Mészáros, G, Vásárhelyi, B, Fischer, K, Szabó, A & Treszl, A 2009, 'Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients', Journal of International Medical Research, vol. 37, no. 6, pp. 1982-1987.
Mácsai, E. ; Cseh, Á ; Budai, G. ; Mészáros, G. ; Vásárhelyi, B. ; Fischer, K. ; Szabó, A. ; Treszl, A. / Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients. In: Journal of International Medical Research. 2009 ; Vol. 37, No. 6. pp. 1982-1987.
@article{81c84113e0cf44599aa8cc6f0013b280,
title = "Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients",
abstract = "Doxazosin, an α1-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4+, CD8+, CD25+ and CD69+ cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4 +CD25+high cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4+CD69+ and CD8+CD69+ cells) decreased, whereas that of regulatory Tcells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.",
keywords = "α-Adrenergic receptor inhibitor, Doxazosin, Immunomodulation, Lymphocytes, Proteinuria, Regulatory T-cells, Type 2 diabetes",
author = "E. M{\'a}csai and {\'A} Cseh and G. Budai and G. M{\'e}sz{\'a}ros and B. V{\'a}s{\'a}rhelyi and K. Fischer and A. Szab{\'o} and A. Treszl",
year = "2009",
language = "English",
volume = "37",
pages = "1982--1987",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "6",

}

TY - JOUR

T1 - Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients

AU - Mácsai, E.

AU - Cseh, Á

AU - Budai, G.

AU - Mészáros, G.

AU - Vásárhelyi, B.

AU - Fischer, K.

AU - Szabó, A.

AU - Treszl, A.

PY - 2009

Y1 - 2009

N2 - Doxazosin, an α1-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4+, CD8+, CD25+ and CD69+ cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4 +CD25+high cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4+CD69+ and CD8+CD69+ cells) decreased, whereas that of regulatory Tcells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.

AB - Doxazosin, an α1-adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. The prevalence of CD4+, CD8+, CD25+ and CD69+ cells at baseline and after 3 months of add-on therapy was determined. The prevalence of regulatory T-cells was detected by two different approaches: forkhead box P3 (FoxP3) positivity; and the number of CD4 +CD25+high cells. During 3 months of doxazosin therapy, patients' blood pressure, blood glucose control and lipid profiles all significantly improved. Simultaneously, the prevalence of activated T-cells (CD4+CD69+ and CD8+CD69+ cells) decreased, whereas that of regulatory Tcells increased. These results indicate an immunomodulatory action of doxazosin in type 2 diabetic patients.

KW - α-Adrenergic receptor inhibitor

KW - Doxazosin

KW - Immunomodulation

KW - Lymphocytes

KW - Proteinuria

KW - Regulatory T-cells

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=74949108630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949108630&partnerID=8YFLogxK

M3 - Article

C2 - 20146898

AN - SCOPUS:74949108630

VL - 37

SP - 1982

EP - 1987

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 6

ER -